ArticleThe International journal on drug policy2026
Early effects of scheduling gabapentin on medication adherence among epilepsy patients on gabapentin in Virginia.
Article in The International journal on drug policy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundDue to concerns about misuse and diversion, eight states have scheduled gabapentin as a controlled substance. The effect of this change on patient adherence is unknown.
objectivesTo estimate the effect of Virginia's scheduling of gabapentin on medication adherence among epilepsy patients. RESEARCH
designUsing all-payer claims data from Virginia and Colorado for 2017-2019, we identified patients with focal seizures who had a claim for gabapentin, pregabalin, or levetiracetam. The primary outcome was proportion of days covered over six-month periods. Effects were estimated using a triple-difference approach comparing patients 1) pre- vs. post-policy, 2) in Virginia vs. Colorado, and 3) on gabapentin vs a comparison medication. Analyses were repeated excluding patients with opioid claims.
resultsGabapentin scheduling in Virginia was associated with a 3.6 (SD: 1.1, p-value <0.001) percentage point decrease in proportion of days covered. The share of epilepsy patients with ≥80% of days covered decreased from 67.5% to 60.2% (adjusted difference: -7.5%, SD: 2.2, p-value <0.001). The proportion of gabapentin patients with a concurrent opioid prescription did not significantly change and excluding these patients had minimal effect.
conclusionsIn the six months following Virginia's policy change, scheduling gabapentin was associated with a decline in the proportion of days covered among epilepsy patients. Given ongoing state-level gabapentin policy changes, continued research on the impacts of scheduling gabapentin on patient care and barriers to medication access is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.